OBJECTIVE-Berardinelli-Seip congenital lipodystrophy type 2 (BSCL2) is a recessive disorder featuring near complete absence of adipose tissue. Remarkably, although the causative gene, BSCL2, has been known for several years, its molecular function and its role in adipose tissue development have not been elucidated. Therefore, we examined whether BSCL2 is involved in the regulation of adipocyte differentiation and the mechanism whereby pathogenic mutations in BSCL2 cause lipodystrophy.
M
etabolic homeostasis requires the ability to expand adipose tissue appropriately, as illustrated by lipodystrophy, in which inability to increase adipose tissue mass commonly leads to severe hypertriglyceridemia, insulin resistance, and diabetes due to ectopic lipid accumulation in other tissues (1) . Identifying the key genes and regulatory processes involved in adipocyte development is likely to enhance understanding of both pathologically increased and decreased adipose mass.
Several different genetic defects in human lipodystrophy have been identified. Some affect genes with a wellestablished role in adipogenesis or lipid metabolism, such as PPARG, AKT2, and l-acylglycerol-3-phosphate 0-acyltransferate2 (AGPAT2) (1) . The role of others, such as LMNA and ZMPSTE, is less clear, although defects in LMNA do perturb adipocyte differentiation in a cell-autonomous manner (2) . In contrast, although mutations in BSCL2 produce more severe adipose tissue loss than any of these other genetic defects, very little is known about the underlying pathogenic mechanism (3, 4) . The global adipose deficit in affected individuals has led to speculation that BSCL2 is involved in stem cell determination toward the adipogenic lineage (5) . An alternative suggestion, based on reports of relatively high expression in the central nervous system, is that lipodystrophy results from loss of a key central function of BSCL2 (3) (4) (5) (6) . A recent study has described abnormal lipid droplet formation in yeast lacking the BSCL2 orthologue, YLR404W, and a similar defect in fibroblasts isolated from a BSCL2-deficient patient (7) . However, the localization and function of BSCL2 in differentiating or mature adipocytes remains to be elucidated, as does the molecular mechanism whereby BSCL2 mutations cause lipodystrophy. BSCL2/Seipin AND ADIPOCYTE DIFFERENTIATION was induced using the same regimen as for C3H10T1/2 cells and 3T3-L1 adipocytes. Oil red O staining of lipid accumulation was performed as previously described (8) . Retrovirus-mediated short hairpin RNA knockdown. Two short hairpin RNA (shRNA) sequences targeting BSCL2 were designed and cloned into the RNAi-Ready pSIREN-RetroQ vector (BD Biosciences Clontech). Retroviral packaging BOSC-HEK293 cells were transfected with both these constructs and a control shRNA vector to generate retroviruses to infect C3H10T1/2 cells. Virus collection, preparation, and cell infection were performed as previously described (9) . Western blotting and immunofluorescence. Protein samples were prepared as previously described (8) . A total of 30 g protein was denatured and analyzed by Western blotting, using antibodies to C/EBP␤, C/EBP␦, and ETO (Santa Cruz Biotechnology); myc (4G10, UBI); and calnexin (AbCam). For immunofluorescence studies, cells were grown on glass coverslips, fixed in 10% formalin, permeablized with 0.5% saponin, blocked with 1% BSA, and probed with antibodies diluted in 1% BSA. Coverslips were mounted in ProLong Gold medium (Invitrogen) and analyzed on a Zeiss 510 Meta confocal microscope.
RESULTS
Previous studies reporting the tissue distribution of BSCL2, as assessed by Northern blotting, have reported highest expression in the brain (4) or did not determine adipose tissue expression (11) . Quantification of BSCL2 using real-time PCR in a range of mouse tissues demonstrated that expression was highest in subcutaneous and epididymal white adipose depots and interscapular brown adipose tissue (Fig. 1A) . Expression in whole brain was ϳ20 -35% that in adipose tissue, leading us to speculate that BSCL2 mutations may cause lipodystrophy via direct effects in adipose tissue.
To examine the earliest stages of cell commitment to the adipocyte lineage, we investigated the expression of BSCL2 in murine embryonic stem cell embryoid bodies during differentiation to adipocytes. Treatment with adipogenic medium increased BSCL2 expression in these cells within 24 h, and expression continued to rise as the number of adipocytes increased (Fig. 1B) . The time course of induction was similar to that of the key adipocyte markers PPAR␥ 2 and C/EBP␣ (Figs. S1A and B [available in an online appendix at http://dx.doi.org/10.2337/db08-0184]), suggesting a role for BSCL2 in terminal adipocyte differentiation rather than early stem cell commitment. Consistent with this finding, adipogenic induction of C3H10T1/2 mesenchymal cells significantly increased BSCL2 expression, apparent after 24 h and strongly induced after 3 days (Fig. 1C) . Again, this pattern of expression was similar to that of PPAR␥ 2 and C/EBP␣ (Fig. S1C  and D) . A similar, albeit delayed, induction of BSCL2 expression also occurs in differentiating 3T3-L1 preadipo- (Fig. S1E) , with a transient additional peak at day 8 of differentiation. BSCL2 mRNA expression was also induced in differentiating isolated primary mouse (Fig. 1D) and human (Fig. 1E) preadipocytes, remaining raised in the mature adipocytes. Moreover, BSCL2 mRNA was most abundant in the mature adipocyte rather than in stem cell/preadipocyte-containing stromovascular fraction of both mouse (Fig. 1F) and human (Fig. 1G) 
Previous studies have demonstrated that BSCL2 is localized in the endoplasmic reticulum in nonadipogenic cell lines (11, 12) and that BSCL2 is inserted in the endoplasmic reticulum membrane (13) . Next, we generated C3H10T1/2 cells stably expressing myc-tagged BSCL2. Following differentiation to adipocytes, BSCL2 was found to be also mainly colocalized with the endoplasmic reticulum membrane protein calnexin (Fig. 1H) . Similar colocalization was also observed with the endoplasmic reticulum marker calreticulin (data not shown), demonstrating that the majority of BSCL2 is found in this compartment in adipocytes.
To test the importance of BSCL2 in developing adipocytes, we generated two C3H10T1/2 cell lines stably expressing shRNA species targeting BSCL2. Real-time PCR revealed that both BSCL2 shRNAs effectively inhibited the expression of BSCL2 (Fig. 2A) . Following differentiation for 8 days, lipid accumulation was severely impaired in cells lacking BSCL2 (Fig. 2B) , as was the induction of the adipogenic transcription factors C/EBP␣, PPAR␥ 1 , PPAR␥ 2 , and sterol regulatory element binding protein-1c (SREBP1c) (Fig. 2C ). These cells also had significantly reduced expression of GLUT4, diacylglycerol O-acyltransferase 2 (DGAT2), lipoprotein lipase, and aP2 (Fig. 2D) , demonstrating that the induction of BSCL2 is important for normal adipogenesis.
The induction and activation of C/EBP␤ and C/EBP␦ are the best-characterized early events in adipogenesis and are critical for the subsequent induction of the central regulators of this process, C/EBP␣ and PPAR␥ (14) . When BSCL2 knockdown cells were induced to differentiate for various times up to 72 h, the induction of C/EBP␤ and C/EBP␦ mRNA (Figs. 3A and B, respectively) and protein ( Fig. 3C ) was equivalent to that in control cells. The rapid suppression of ETO, an inhibitor of C/EBP␤ (9), was also normal in cells lacking BSCL2 (Fig. 3C) . Despite the decreased expression of C/EBP␣ and PPAR␥ 2 mRNAs at later time points (Fig. 2C) , the early induction of these factors was also not consistently reduced by loss of BSCL2 expression (Fig. 3D and E) . In contrast, the expression of RNA encoding SREBP1c was dramatically decreased in cells lacking BSCL2 at the same time points (Fig. 3F) , as was the expression of key enzymes of triglyceride synthesis, AGPAT2 (Fig. 3G), DGAT2 (Fig.  3H) , and lipin 1␤ (Fig. 3I) .
Having examined how BSCL2 loss results in a failure of adipogenesis, we examined how pathogenic mutations in BSCL2 may result in the loss of its functional activity. The majority of mutations in BSCL2 causing lipodystrophy generate very short or mostly nonsense proteins (6) . This, together with the recessive inheritance pattern, indicates that complete loss of BSCL2 function is required for the development of lipodystrophy. The longest reported premature stop mutation, R275X, is truncated just after the second transmembrane domain, resulting in a predicted protein lacking only the COOH-terminal cytoplasmic tail (4, 15) . In addition, one lipodystrophy-associated missense mutation has been described, causing substitution of alanine at codon 212 for proline (4) . Cells were transiently transfected with constructs encoding either wild-type, R275X, or A212P human BSCL2. Real-time PCR detecting human BSCL2 mRNA in this murine cell line revealed similar transcript levels of wild-type, R275X, and A212P BSCL2 (Fig. 4A) . When lysates from identically treated cells were Western blotted for the transfected proteins, 
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BSCL2 protein appeared as a high-molecular weight complex (Fig. 4B) . The severely impaired mobility of BSCL2 on SDS-PAGE may result from aggregation due to hydrophobicity of this transmembrane protein and is consistent with previous studies in which the majority of BSCL2 runs at a molecular weight of 250 kDa (12) . While both wildtype and A212P proteins were clearly detectable, the R275X protein was not, strongly suggesting that the protein is either rapidly degraded or not translated. When assessed by immunofluorescence, we found that, unlike wild-type BSCL2, a substantial proportion of A212P-BSCL2 was localized to the nuclear envelope (Fig. 4C) . Consistent with our Western blot data, R275X-BSCL2 was undetectable by immunofluorescence (data not shown).
DISCUSSION
We show that BSCL2 expression is critical for normal adipogenesis to occur in vitro. The recent demonstration that loss of BSCL2 causes a defect of lipid droplet morphology led the authors to suggest that defective lipid droplet formation is the primary cause of BSCL2 disease (7) . We show that cells lacking BSCL2 fail to induce the expression of SREBP1c and the lipogenic enzymes AGPAT2, DGAT2, and lipin 1. This is evident within 24 h of the induction of adipogenesis, before lipid droplets usually form in these cells. Thus, we propose that a failure to induce adipogenic transcriptional events makes a major contribution to the development of this phenotype.
The failure to maintain PPAR␥ expression in BSCL2 knockdown cells during the later stages of adipogenesis is consistent with reports that loss of either AGPAT2 or lipin 1 inhibits adipogenic gene expression and triglyceride synthesis (16 -18) . Loss of AGPAT2 activity causes lipodystrophy in humans (BSCL type 1), and lipin 1 disruption causes lipodystrophy in the fld mouse (19, 20) . Moreover, DGAT2-deficient mice suffer severe lipopenia (21) . Our data strongly suggest that individuals lacking BSCL2 may fail to induce the expression of these key lipogenic enzymes during adipogenesis in vivo, which may explain a phenotype more severe than that associated with loss of AGPAT2 alone.
Failure to induce SREBP1c expression in cells lacking BSCL2 may compound, or perhaps cause, these geneexpression changes. SREBP1c both directly activates transcription of adipogenic genes and enhances production of an endogenous ligand for PPAR␥ ( cells is believed to be driven largely by C/EBP␤ and C/EBP␦, which are unaffected by loss of BSCL2 (Fig. 3) . However, PPAR␥ normally acts to sustain the expression of PPAR␥ and C/EBP␣ in the maturing adipocyte. Hence, loss of SREBP1c-dependent PPAR␥ ligand production may contribute to decreased PPAR␥ and C/EBP␣ expression in maturing adipocytes lacking BSCL2. Our data also give novel insight into the mechanism linking two BSCL2 mutants to generalized lipodystrophy. First, the truncated R275X protein is not expressed in cells, suggesting that individuals homozygous for this mutation may be effectively null for BSCL2 expression. Second, the A212P mutant of BSCL2 exhibits aberrant accumulation in the nuclear envelope. The failure of this mutant to support adipose tissue formation in vivo strongly implies that it is functionally inactive. Given the critical importance of this residue, this mutant may be particularly useful in future mechanistic studies of BSCL2 function.
These data demonstrate that BSCL2 plays an important role in the development of mature adipocytes and strongly suggest that the nearly global lack of adipose tissue in patients with BSCL2 mutations is a consequence of a cell-autonomous defect of adipogenesis. This provides the first mechanistic insight into how BSCL2 mutations cause severe lipodystrophy.
